Camurus (0RD1) Stock Overview
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 0RD1 from our risk checks.
0RD1 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 587.49 |
| 52 Week High | SEK 749.00 |
| 52 Week Low | SEK 433.00 |
| Beta | 0.51 |
| 1 Month Change | -3.69% |
| 3 Month Change | 16.81% |
| 1 Year Change | -18.91% |
| 3 Year Change | 99.02% |
| 5 Year Change | 237.64% |
| Change since IPO | 791.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RD1 | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -2.2% | -3.4% | -0.7% |
| 1Y | -18.9% | 1.8% | 16.1% |
Return vs Industry: 0RD1 underperformed the UK Pharmaceuticals industry which returned 2.8% over the past year.
Return vs Market: 0RD1 underperformed the UK Market which returned 17.3% over the past year.
Price Volatility
| 0RD1 volatility | |
|---|---|
| 0RD1 Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RD1 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0RD1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 316 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| 0RD1 fundamental statistics | |
|---|---|
| Market cap | SEK 35.02b |
| Earnings (TTM) | SEK 678.17m |
| Revenue (TTM) | SEK 2.27b |
Is 0RD1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RD1 income statement (TTM) | |
|---|---|
| Revenue | SEK 2.27b |
| Cost of Revenue | SEK 157.01m |
| Gross Profit | SEK 2.11b |
| Other Expenses | SEK 1.43b |
| Earnings | SEK 678.17m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | 11.40 |
| Gross Margin | 93.07% |
| Net Profit Margin | 29.92% |
| Debt/Equity Ratio | 0% |
How did 0RD1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/09 13:32 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Camurus AB (publ) is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Gonzalo Artiach Castanon | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |